Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-exendin-4 PET-CT in Diabetes
NCT05662189Recruiting
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Mar 2022
- Primary completion
- Jul 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label trial of gallium-68-DOTA-exendin-4 (7 arms), sponsored by Azienda Ospedaliero-Universitaria di Parma. Primary endpoints: Beta Cell Functional Mass at 3 months, Pancreatic Beta Cell Mass at 3 months and 1 more. Started Mar 2022; status: recruiting.
02
Drugs
gallium-68-DOTA-exendin-4
Beyond the preview
Go deeper on NCT05662189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662189.